Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor.

The Journal of pathology - 1 Feb 2013

Barber Louise J, Sandhu Shahneen, Chen Lina, Campbell James, Kozarewa Iwanka, Fenwick Kerry, Assiotis Ioannis, Rodrigues Daniel Nava, Reis Filho Jorge S, Moreno Victor, Mateo Joaquin, Molife L Rhoda, De Bono Johann, Kaye Stan, Lord Christopher J, Ashworth Alan

Abstract excerpt

PARP inhibitors (PARPi) for the treatment of BRCA1 or BRCA2 deficient tumours are currently the focus of seminal clinical trials exploiting the concept of synthetic lethality. Although clinical resistance to PARPi has been described, the mechanism underlying this has not been elucidated. Here, we investigate tumour material from patients who had developed resistance to the PARPi olaparib, subsequent to showing an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms, Male

Share to Combined Modality Therapy

Share to Ovarian Neoplasms

Share to Phthalazines

Share to Piperazines

Share to Poly(ADP-ribose) Polymerase Inhibitors

Source

Identifiers

PMID: 23165508
DOI: 10.1002/path.4140

Genes

BRCA2
BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor.PMID 23165508Read ↗

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistanceSemantic proximity Read ↗

Resistance to PARP Inhibitors: Lessons from Preclinical Models of BRCA-Associated CancerSemantic proximity Read ↗

BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challengesSemantic proximity Read ↗

Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP InhibitorsSemantic proximity Read ↗

<i>BRCA1</i> secondary splice-site mutations drive exon-skipping and PARP inhibitor resistanceSemantic proximity Read ↗

PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reportsSemantic proximity Read ↗

Mechanisms of resistance to therapies targeting BRCA-mutant cancers.Semantic proximity Read ↗

Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion MutationsSemantic proximity Read ↗

Investigation of PARP Inhibitor Resistance Based on Serially Collected Circulating Tumor DNA in Patients With BRCA -Mutated Ovarian CancerSemantic proximity Read ↗

Metastatic lung adenocarcinoma with BRCA2 mutation and longstanding disease control on olaparib, developing triple negative breast adenocarcinoma with additional BRCA2 reversion mutation: a case report.Semantic proximity Read ↗

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation CarriersSemantic proximity Read ↗

BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.